Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma.

IF 2 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Biomarkers Pub Date : 2024-03-01 Epub Date: 2024-02-15 DOI:10.1080/1354750X.2024.2312990

Chika Nakagawa, Tsunekazu Oikawa, Kohji Yamada, Akihito Tsubota, Chisato Saeki, Kuniko Katagiri, Naoko Tago, Hiroshi Kamioka, Kaoru Ueda, Koichiro Haruki, Kenei Furukawa, Masanori Nakano, Yuichi Torisu, Toru Ikegami, Kiyotsugu Yoshida, Masayuki Saruta

{"title":"Protein kinase C delta enhances the diagnostic performance of hepatocellular carcinoma.","authors":"Chika Nakagawa, Tsunekazu Oikawa, Kohji Yamada, Akihito Tsubota, Chisato Saeki, Kuniko Katagiri, Naoko Tago, Hiroshi Kamioka, Kaoru Ueda, Koichiro Haruki, Kenei Furukawa, Masanori Nakano, Yuichi Torisu, Toru Ikegami, Kiyotsugu Yoshida, Masayuki Saruta","doi":"10.1080/1354750X.2024.2312990","DOIUrl":null,"url":null,"abstract":"Background: The conventional markers for hepatocellular carcinoma (HCC), α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), have several limitations; both have low sensitivity in patients with early-stage HCC; low sensitivity for AFP with HCC after eliminating hepatitis C virus (HCV); low specificity for DCP in patients with non-viral HCC, which is increasing worldwide; low specificity for AFP in patients with liver injury; and low specificity for DCP in patients treated with warfarin. To overcome these issues, the identification of novel biomarkers is an unmet need.Objective: This study aimed to assess the usefulness of serum protein kinase C delta (PKCδ) for detecting these HCCs.Methods: PKCδ levels were measured using a sandwich enzyme-linked immunosorbent assay in 363 chronic liver disease (CLD) patients with and without HCC.Results: In both viral and non-viral CLD, PKCδ can detect HCCs with high sensitivity and specificity, particularly in the very early stages. Notably, the value and sensitivity of PKCδ were not modified by HCV elimination status. Liver injury and warfarin administration, which are known to cause false-positive results for conventional markers, did not modify PKCδ levels.Conclusions: PKCδ is an enhanced biomarker for the diagnosis of HCC that compensates for the drawbacks of conventional markers.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"55-67"},"PeriodicalIF":2.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2024.2312990","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The conventional markers for hepatocellular carcinoma (HCC), α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP), have several limitations; both have low sensitivity in patients with early-stage HCC; low sensitivity for AFP with HCC after eliminating hepatitis C virus (HCV); low specificity for DCP in patients with non-viral HCC, which is increasing worldwide; low specificity for AFP in patients with liver injury; and low specificity for DCP in patients treated with warfarin. To overcome these issues, the identification of novel biomarkers is an unmet need.

Objective: This study aimed to assess the usefulness of serum protein kinase C delta (PKCδ) for detecting these HCCs.

Methods: PKCδ levels were measured using a sandwich enzyme-linked immunosorbent assay in 363 chronic liver disease (CLD) patients with and without HCC.

Results: In both viral and non-viral CLD, PKCδ can detect HCCs with high sensitivity and specificity, particularly in the very early stages. Notably, the value and sensitivity of PKCδ were not modified by HCV elimination status. Liver injury and warfarin administration, which are known to cause false-positive results for conventional markers, did not modify PKCδ levels.

Conclusions: PKCδ is an enhanced biomarker for the diagnosis of HCC that compensates for the drawbacks of conventional markers.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

蛋白激酶 C delta 可提高肝细胞癌的诊断性能。

背景：肝细胞癌（HCC）的传统标志物--α-胎儿蛋白（AFP）和去γ-羧基凝血酶原（DCP）--有几个局限性；两者对早期 HCC 患者的敏感性都很低；消除丙型肝炎病毒（HCV）后，AFP 对 HCC 的敏感性较低；DCP 对非病毒性 HCC 患者的特异性较低，而这种情况在全球范围内正日益增多；AFP 对肝损伤患者的特异性较低；DCP 对接受华法林治疗的患者的特异性较低。为了克服这些问题，鉴定新型生物标志物是一项尚未满足的需求：本研究旨在评估血清蛋白激酶 C δ（PKCδ）在检测这些 HCCs 中的作用：方法：采用夹心酶联免疫吸附测定法检测363名患有和未患有HCC的慢性肝病（CLD）患者的PKCδ水平：结果：在病毒性和非病毒性CLD中，PKCδ都能以较高的灵敏度和特异性检测出HCC，尤其是在早期阶段。值得注意的是，PKCδ的价值和灵敏度不受HCV消除状态的影响。众所周知，肝损伤和服用华法林可导致传统标记物出现假阳性结果，但它们并不会改变PKCδ的水平：结论：PKCδ是一种用于诊断HCC的增强型生物标记物，可弥补传统标记物的不足。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.